ORCID ID
0000-0002-8905-1589
Publication Date
2019-03-28
Document Type
Doctoral Dissertation
Academic Program
Interdisciplinary Graduate Program
Department
Gene Therapy Center; Neurology
First Thesis Advisor
Christian Mueller PhD
Second Thesis Advisor
Robert H. Brown DPhil, MD
Keywords
ALS, C9ORF72, Gene therapy for ALS, microRNAs, Epigenetics in ALS, C9ORF72 mouse model, Silencing of C9ORF72
Abstract
Amyotrophic lateral sclerosis (ALS) is a terminal neurodegenerative disease that affects motor neurons causing progressive muscle weakness and respiratory failure. In 2011, the presence of a hexanucleotide repeat expansion within chromosome 9 open reading frame 72(C9ORF72) was identified in ALS patient samples, becoming the major known genetic cause for ALS and frontotemporal dementia (FTD). Carriers of this mutation present reduced levels of C9ORF72 mRNA, RNA foci produced by the aggregating expansion and toxic dipeptides generated through repeat-associated non-ATG translation. These findings have led to multiple hypotheses on the pathogenesis of C9ORF72: 1) Haploinsufficiency, 2) RNA gain-of-function, 3) RAN Translation, and 4) Disrupted nucleocytoplasmic trafficking. Due to lack of treatments for this disease, we have pursued an AAV-RNAi dependent gene therapy approach, using an artificial microRNA (amiR) packaged in a recombinant adeno-associated virus (rAAV). After validating our in vitro results, we advanced to in vivo experiments using transgenic mice that recapitulate the major histopathological features seen in human ALS/FTD patients. Adult and neonate mice were injected through clinically relevant routes and our results indicate that AAV9-mediated amiR silencing not only reduced mRNA and protein levels of C9ORF72 but also the expansion derived toxic GP dipeptides. Although our amiR is not targeting the expansion itself but exon 3, we illustrate here that the evident dipeptide decrease is achievable due to the presence of aberrant transcripts in the cytoplasm containing miss-spliced Intron-HRE-C9ORF72 species. These encouraging results have led to the continued testing of this treatment as a therapeutic option for C9ORF72 - ALS patients.
Repository Citation
Toro G. (2019). Gene Therapy for Amyotrophic Lateral Sclerosis: An AAV Mediated RNAi Approach for Autosomal Dominant C9ORF72 Associated ALS. GSBS Dissertations and Theses. https://doi.org/10.13028/kw7m-9a26. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/1020
DOI
10.13028/kw7m-9a26
DOI Link
Rights and Permissions
Copyright is held by the author, with all rights reserved.
Included in
Animal Experimentation and Research Commons, Molecular and Cellular Neuroscience Commons, Nervous System Diseases Commons, Virology Commons